Isabel Coutinho

Isabel Coutinho

Auto-generated profile, based on publicly available information

Isabel Coutinho

Dame Roma Mitchell Cancer Research Laboratories, Adelaide Medical School, The University of Adelaide, South Australia, Australia

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Endocrine-Related Cancer
Verified
Journal Article
Closed access
PDF file
ICIsabel Coutinho
Isabel Coutinho
TDTanya K Day
Tanya K Day
WTWayne Tilley
Wayne Tilley
LSLuke Selth
Luke Selth
The androgen receptor (AR) signaling axis drives all stages of prostate cancer, including the lethal, drug-resistant form of the disease termed castration-resistant prostate cancer (CRPC), which arises after failure of androgen deprivation therapy (ADT). Persistent AR activity in spite of ADT and the second-generation AR-targeting agents enzalutamide and abiraterone is achieved in many cases by direct alterations to the AR signaling axis. Herein, we provide a detailed description of how such alterations contribute to the development and progression of CRPC. Aspects of this broad and ever-evolving field specifically addressed in this review include: the etiology and significance of increased AR expression; the frequency and role of gain-of-function mutations in theARgene; the function of constitutively active, truncated forms of the AR termed AR variants and the clinical relevance of alterations to the activity and expression of AR coregulators. Additionally, we examine the novel therapeutic strategies to inhibit these classes of therapy resistance mechanisms, with an emphasis on emerging agents that act in a manner distinct from the current ligand-centric approaches. Throughout, we discuss how the central role of AR in prostate cancer and the constant evolution of the AR signaling axis during disease progression represent archetypes of two key concepts in oncology, oncogene addiction and therapy-mediated selection pressure.

1 July 2017 in Cancer Research
Verified
Journal Article
Closed access
PDF file
SPSteve Paltoglou
Steve Paltoglou
RDRajdeep Das
Rajdeep Das
STScott L. Townley
Scott L. Townley
THTheresa Elizabeth Hickey
Theresa Elizabeth Hickey
GTGerard Tarulli
Gerard Tarulli
LSLuke Selth
Luke Selth
Alteration to the expression and activity of androgen receptor (AR) coregulators in prostate cancer is an important mechanism driving disease progression and therapy resistance. Using a novel proteomic technique, we identified a new AR coregulator, the transcription factor Grainyhead-like 2 (GRHL2), and demonstrated its essential role in the oncogenic AR signaling axis. GRHL2 colocalized with AR in prostate tumors and was frequently amplified and upregulated in prostate cancer. Importantly, GRHL2 maintained AR expression in multiple prostate cancer model systems, was required for cell proliferation, enhanced AR's transcriptional activity, and colocated with AR at specific sites on chromatin to regulate genes relevant to disease progression. GRHL2 is itself an AR-regulated gene, creating a positive feedback loop between the two factors. The link between GRHL2 and AR also applied to constitutively active truncated AR variants (ARV), as GRHL2 interacted with and regulated ARVs and vice versa. These oncogenic functions of GRHL2 were counterbalanced by its ability to suppress epithelial–mesenchymal transition and cell invasion. Mechanistic evidence suggested that AR assisted GRHL2 in maintaining the epithelial phenotype. In summary, this study has identified a new AR coregulator with a multifaceted role in prostate cancer, functioning as an enhancer of the oncogenic AR signaling pathway but also as a suppressor of metastasis-related phenotypes. Cancer Res; 77(13); 3417–30. ©2017 AACR.

6 June 2016 in Oncogene
Verified
Journal Article
Closed access
LSLuke Selth
Luke Selth
RDR Das
R Das
STS L Townley
S L Townley
ICI Coutinho
I Coutinho
AHA R Hanson
A R Hanson
WTWayne Tilley
Wayne Tilley

5 March 2011 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PGPaulo M.C. Glória
Paulo M.C. Glória
ICIsabel Coutinho
Isabel Coutinho
Luís Miguel GoncalvesLuís Miguel Goncalves
Luís Miguel Goncalves
CBCristina Baptista
Cristina Baptista
JSJoana Soares
Joana Soares
Maria SantosMaria Santos
Maria Santos

17 October 2009 in FEBS Letters
Verified
Journal Article
Closed access
ICIsabel Coutinho
Isabel Coutinho
GPGil Pereira
Gil Pereira
MLMariana Leão
Mariana Leão
Jorge GonçalvesJorge Gonçalves
Jorge Gonçalves
MCManuela Côrte-Real
Manuela Côrte-Real
Lucília SaraivaLucília Saraiva
Lucília Saraiva